Latest Media Releases

All A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

IVE Group - Investor Presentation Half Year Results (31 December 2020) (ASX:IGL)

To view the presentation, download the attached PDF.

IVE Group Announces Half Year Results to 31 December 2020 (ASX:IGL)

IVE Group Limited (IVE Group or The Company, ASX:IGL) is pleased to announce its results for the six months ended 31 December 2020 (1H FY21). The strength of IVE's client relationships, flexi...read more

IVE Group - Appendix 4D and Half Year Results to 31 December 2020 (ASX:IGL)

This information should be read in conjunction with the 31 December 2020 Interim Consolidated Financial Report of IVE Group Limited and its controlled entities and any public announcements made in t...read more

IVE Group - Dividend/Distribution (ASX:IGL)

To view the Notification of dividend / distribution, download the attached PDF.

Immutep - Half Yearly Report and Accounts (ASX:IMM)

To view the Appendix 4D and Half-Year Financial Report, download the attached PDF.

Immutep - Phase II study for eftilagimod alpha in COVID-19 advances (ASX:IMM)

Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a biotechnology company developing novel immunotherapy treatments for cancer and autoimmune disease, ann...read more

Immutep Quarterly Activities Report & Appendix 4C (ASX:IMM)

Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a biotechnology company developing novel immunotherapy treatments for cancer and autoimmune disease, pro...read more

Immutep - Ulcerative Colitis Phase II Study of GSK2831781 Discontinued (ASX:IMM)

Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a biotechnology company developing novel immunotherapy treatments for cancer and autoimmune disease, adv...read more

Immutep - Recruitment of head & neck cancer patients completed for ph2 (ASX:IMM)

Immutep Limited (ASX: IMM; NASDAQ: IMMP) a biotechnology company developing novel immunotherapy treatments for cancer and autoimmune diseases, is pleased to report it has enrolled and safely dosed t...read more

Immutep - Resignation and Appointment of Joint Company Secretary (ASX:IMM)

ASX and NASDAQ listed biotechnology company Immutep Limited (“Immutep“ or the “Company“), advises that Mr Tom Bloomfield has resigned as the joint Company Secretary of the Co...read more

Immutep - Change in substantial holding (ASX:IMM)

To view the Notice of change of interests of substantial holder, download the attached PDF.

Immutep - Appendix 2A (ASX:IMM)

To view the Application for quotation of +securities, download the attached PDF.

Immutep - Change in substantial holding (ASX:IMM)

To view the Notice of change of interests of substantial holder, download the attached PDF.

Immutep - Change in substantial holding (ASX:IMM)

To view the notice of change of interests of substantial holder, download the attached PDF.

Immutep granted US patent for eftilagimod alpha with a PD-1 (ASX:IMM)

Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep“ or “the Company“), a biotechnology company developing novel immunotherapy treatments for cancer and autoimmune disease, is ...read more

Viewing: 1 - 15 of 200 Previous | Next